Lenz & Staehelin: Hasten acquires Rocephin® commercial rights

Hasten Biopharmaceutic (China) has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche. Under the agreement, Hasten acquired Roche’s China mainland rights for Rocephin®, including the product’s Marketing Authorization, Intellectual Property, trademarks, and technology transfer. Hasten is an investment of CBC Group, Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.

Lenz & Staehelin advised Hasten in this transaction. The team included partner Tino Gaberthüel (pictured) and associate Lukas Held (both m&a), Peter Ling (IP) and Leo Rusterholz (transitional services).